Tacrine

⇄

cytochrome P450 family 1 subfamily A member 2 ; Homo sapiens







30 Article(s)
Download
PMID
Title
Pub. Year
#Total Relationships
1 33397254 Metabolism and Mechanism of Human Cytochrome P450 Enzyme 1A2. 2021 1
2 28400237 Cytochrome P450 binding studies of novel tacrine derivatives: Predicting the risk of hepatotoxicity. 2017 Jun 1 2
3 24910237 Application of a higher throughput approach to derive apparent Michaelis-Menten constants of isoform-selective p450-mediated biotransformation reactions in human hepatocytes. 2014 1
4 19961320 Structure, function, regulation and polymorphism and the clinical significance of human cytochrome P450 1A2. 2010 May 1
5 19590965 Insights into the substrate specificity, inhibitors, regulation, and polymorphisms and the clinical impact of human cytochrome P450 1A2. 2009 Sep 1
6 19702529 Insights into the structure, function, and regulation of human cytochrome P450 1A2. 2009 Sep 1
7 19754423 Synthetic and natural compounds that interact with human cytochrome P450 1A2 and implications in drug development. 2009 1
8 18573860 Characterization of substrate specificity of dog CYP1A2 using CYP1A2-deficient and wild-type dog liver microsomes. 2008 Sep 1
9 18584988 An automated, high-throughput, 384 well Cytochrome P450 cocktail IC50 assay using a rapid resolution LC-MS/MS end-point. 2008 Sep 10 1
10 18634893 Development of an in vitro drug-drug interaction assay to simultaneously monitor five cytochrome P450 isoforms and performance assessment using drug library compounds. 2008 Nov-Dec 1
11 17166674 Re-evaluation of tacrine hepatotoxicity using gel entrapped hepatocytes. 2007 Jan 30 2
12 17823102 Drug interactions with smoking. 2007 Sep 15 1
13 17908053 Pharmacogenetic aspects of therapy with cholinesterase inhibitors: the role of CYP2D6 in Alzheimer's disease pharmacogenetics. 2007 Sep 1
14 16128905 Assessment of CYP1A2 activity in clinical practice: why, how, and when? 2005 Sep 1
15 14533945 Clinically significant drug interactions with cholinesterase inhibitors: a guide for neurologists. 2003 1
16 12162759 Clinical pharmacokinetics and pharmacodynamics of cholinesterase inhibitors. 2002 1
17 10456487 Fluvoxamine is a potent inhibitor of tacrine metabolism in vivo. 1999 Jul 3
18 10594467 Tacrine is not an ideal probe drug for measuring CYP1A2 activity in vivo. 1999 Nov 2
19 10613616 Plasma tacrine concentrations are significantly increased by concomitant hormone replacement therapy. 1999 Dec 2
20 9764962 Caffeine based measures of CYP1A2 activity correlate with oral clearance of tacrine in patients with Alzheimer's disease. 1998 Sep 4
21 9868741 Fluvoxamine is a potent inhibitor of the metabolism of caffeine in vitro. 1998 Dec 2
22 10022747 Use of heterologously expressed human cytochrome P450 1A2 to predict tacrine-fluvoxamine drug interaction in man. 1998 Apr 4
23 9065747 Noninterference of cytochrome P4501A2 in the cytotoxicity of tacrine using genetically engineered V79 Chinese hamster cells for stable expression of the human or rat isoform and two human hepatocyte cell lines. 1997 Feb 7 4
24 9209244 Influence of the CYP1A2 inhibitor fluvoxamine on tacrine pharmacokinetics in humans. 1997 Jun 4
25 9453170 [No relationship between tacrine cytotoxicity and its metabolisation by cytochrome P4501A2]. 1997 2
26 8675160 The caffeine breath test does not identify patients susceptible to tacrine hepatotoxicity. 1996 Jun 4
27 7656503 Clinical pharmacokinetics of tacrine. 1995 Jun 1
28 8565783 Determination of human hepatic cytochrome P4501A2 activity in vitro use of tacrine as an isoenzyme-specific probe. 1995 Sep 8
29 7946932 The effect of enzyme inhibition on the metabolism and activation of tacrine by human liver microsomes. 1994 Jul 1
30 8347124 An investigation into the formation of stable, protein-reactive and cytotoxic metabolites from tacrine in vitro. Studies with human and rat liver microsomes. 1993 Jul 6 1